drugset / Trial / NCT04975256
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2022-11-02
- Completion
- 2022-11-15
Outcome
Outcome not reported
Stopped (Enrollment): “The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | Oral |
| Subject | BI 1701963 | Small molecule | — | — |